|
Pharma is employing AI to support approval submissions by predicting how regulators will react before data is submitted.
|
 |
|
Completion of the transaction is expected in the fourth quarter of 2026.
|
|
|
SpliSense is currently conducting a Phase IIb trial with its antisense oligonucleotide therapy.
|
|
|
The COMP noted early clinical data indicate Zoci may demonstrate a more favourable effect than existing authorised therapies.
|
|
|
The expanded licensing lets AviadoBio pursue partnerships for broader applications, including cardiovascular, nephrology, oncology, and beyond the CNS.
|
|
|
New data for Talvey and Tecvayli was presented at the annual meeting as J&J directs its therapies in earlier-line settings.
|
|
